AcelRx Pharmaceuticals, Inc. (ACRX)
(Delayed Data from NSDQ)
$3.66 USD
+0.10 (2.81%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.65 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Talphera, Inc. [ACRX]
Reports for Purchase
Showing records 1 - 20 ( 176 total )
Company: Talphera, Inc.
Industry: Medical - Drugs
New Year, New Name; AcelRx Transforms Into Talphera As Focus Shifts to Niyad For CRRT; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Company: Talphera, Inc.
Industry: Medical - Drugs
Quantitative Market Research Study Shows Significant Need For Safe and Effective CRRT Anticoagulant; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Talphera, Inc.
Industry: Medical - Drugs
Niyad Could Be a Safer CRRT Anticoagulant With Other Positive Attributes; NEPHRO CRRT Study Begins in 4Q23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
3Q Recap; NEPHRO CRRT Niyad Single Registrational Study Initiates in 4Q23; We Expect PMA Submission in 2H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
IDE Approval Enables Niyad Registrational Study''s Initiation in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Talphera, Inc.
Industry: Medical - Drugs
AcelRx Can''t Seem to Catch a Break; Niyad EUA Declined Because FDA Just Too Busy Right Now; Affirm Buy; PT Cut to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
2Q Recap; Our All-New Model Is Focused on Niyad, With EUA Approval Likely This Year; Upgrade to Buy; $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
1Q Recap; AcelRx Begins a New Chapter With DSUVIA Divested; Niyad U.S. EUA Approval Expected in 3Q; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
DSUVIA Divestment Done; Balance Sheet Now Debt- Free; Maintain Neutral on Uncertain Financial Outlook
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
4Q Recap; Two Regulatory Filings Expected in 2Q23; DSUVIA Divestment to Alora Closing Next Week; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Talphera, Inc.
Industry: Medical - Drugs
DSUVIA Divestment Implements a Long-Awaited Decision to Move on; Niyad EUA on Target in 1H23; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Talphera, Inc.
Industry: Medical - Drugs
Publications Highlight DSUVIA Real World Benefits; Awaiting Strategic Partnership For DSUVIA; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Talphera, Inc.
Industry: Medical - Drugs
3Q Recap; DSUVIA Partnership Expected to Finalize By Year- End 2022; Niyad Moves Closer to EUA; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
2Q Recap: Pivot to Recently Acquired Assets Complete Though Runway Concerns Loom Large; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
1Q Recap; AcelRx Shifts Focus to Clinical Pipeline; Search For DSUVIA U.S. Commercial Partner Begins; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
KOL Event Highlights Niyad''s Potential As a Safer Anticoagulant in Dialysis; Maintain Neutral As We Await DSUVIA Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Talphera, Inc.
Industry: Medical - Drugs
Publication Highlights Potential Benefits of Nafamostat for Anticoagulation of the Dialysis Circuit; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Talphera, Inc.
Industry: Medical - Drugs
4Q Recap: We Finally Throw In the Towel as DSUVIA Sales Disappoint Yet Again
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Talphera, Inc.
Industry: Medical - Drugs
DSUVIA''s Potential in Awake Plastic Surgery Procedures Could Represent a Significant Opportunity; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Talphera, Inc.
Industry: Medical - Drugs
New Publication Highlights Multiple Unique Advantages of DSUVIA Over IV Opioids As Analgesia; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00